Dotmatics

NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development

Phil Mounteney, VP of Science and Technology at Dotmatics, explains in an NBC Las Vegas interview how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines to enable faster and more efficient medical breakthroughs post-COVID.

NBC News Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development

Latest Blogs

Case Studies

White Papers

Upcoming Events

News

Search

NBC Las Vegas Dotmatics - Phil Mounteney

Press O for more options

Video Thumbnail

Click for sound

3:13

How AI is Accelerating Drug Discovery and Vaccine Development

In a featured interview at with NBC Las Vegas, Phil Mounteney, VP of Science and Technology at Dotmatics, explores how AI is revolutionizing drug discovery and vaccine development. From accelerating research timelines to reducing costs and improving drug safety, AI is playing a pivotal role in reshaping the industry post-COVID.

Phil highlights how AI-driven data analysis helps researchers quickly identify promising drug candidates, predict potential safety risks, and optimize development pipelines—all contributing to faster, safer, and more efficient medical breakthroughs.

Watch the full interview to discover how Dotmatics is driving innovation in life sciences and learn how AI is shaping the future of drug discovery.

Learn More About Dotmatics

Schedule a meeting with our product experts today for a personalized demo of Luma's AI capabilities.